openPR Logo
Press release

Tendinopathy Pipeline Analysis 2025: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Therapies, Mechanism of Action, Route of Administration, and Companies by DelveInsight

07-21-2025 08:31 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Tendinopathy Pipeline

Tendinopathy Pipeline

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Tendinopathy pipeline constitutes 5+ key companies continuously working towards developing 5+ Tendinopathy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Tendinopathy Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Tendinopathy Market.

The Tendinopathy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Download sample report to know more about emerging Tendinopathy drugs @ https://www.delveinsight.com/sample-request/tendinopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key takeaways from the Tendinopathy Pipeline Report:
• Tendinopathy Companies across the globe are diligently working toward developing novel Tendinopathy treatment therapies with a considerable amount of success over the years.
• Tendinopathy companies working in the treatment market are Causeway Therapeutics, Novartis, ZARS Pharma Inc., Merck Sharp, Erasmus Medical Center, CTM Biomedical, Zimmer Biomet, 3M, Teikoku Pharma USA Inc., DJO Global Inc., AKSIGEn, and others, are developing therapies for the Tendinopathy treatment
• Emerging Tendinopathy therapies in the different phases of clinical trials are- CWT-001, secukinumab, NGI226, Heated Lidocaine and Tetracaine Patch, etoricoxib, PRP Injection with eccentric exercises, Celestone, and others are expected to have a significant impact on the Tendinopathy market in the coming years.
• In July 2025, Novartis announced results of a Two Part, Randomized, Participant and Investigator-blinded, 2-arm, Parallel-design, Placebo-controlled Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of NGI226 Microparticles on Tendon Regeneration in Patients With Achilles Tendinopathy
• In March 2025, Causeway Therapeutics announced results of a Phase 2, Multi-Centre, Randomised, Double-Blind, Sham Controlled Proof of Concept Trial Evaluating the Efficacy and Safety of TenoMiR by Injection in Subjects With Lateral Epicondylitis
• In February 2025, Novartis announced results of a Randomized, Parallel-group, 24 Week, Double-blind, Placebo-controlled, Multicenter Phase 3 Study to Assess the Efficacy and Safety of Secukinumab Compared to Placebo in Adult Patients With Active Rotator Cuff Tendinopathy

Tendinopathy Overview
Tendinopathy is a condition characterized by pain, swelling, and impaired function of tendons, which are the connective tissues that attach muscles to bones. It occurs due to tendon overuse, repetitive strain, or degeneration rather than inflammation, often affecting tendons in the shoulders, elbows, wrists, knees, and heels. Tendinopathy can develop gradually with symptoms such as stiffness, tenderness, and discomfort during movement, which worsen with continued activity. Common in athletes and individuals with physically demanding jobs, it may be managed through rest, physical therapy, pain management, and, in some cases, surgical intervention for severe cases.

Get a Free Sample PDF Report to know more about Tendinopathy Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/tendinopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Emerging Tendinopathy Drugs Under Different Phases of Clinical Development Include:
• CWT-001: Causeway Therapeutics
• secukinumab: Novartis
• NGI226: Novartis
• Heated Lidocaine and Tetracaine Patch: ZARS Pharma Inc.
• etoricoxib: Merck Sharp
• PRP Injection with eccentric exercises: Erasmus Medical Center
• Celestone: CTM Biomedical

Tendinopathy Route of Administration
Tendinopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Tendinopathy Molecule Type
Tendinopathy Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Tendinopathy Pipeline Therapeutics Assessment
• Tendinopathy Assessment by Product Type
• Tendinopathy By Stage and Product Type
• Tendinopathy Assessment by Route of Administration
• Tendinopathy By Stage and Route of Administration
• Tendinopathy Assessment by Molecule Type
• Tendinopathy by Stage and Molecule Type

DelveInsight's Tendinopathy Report covers around 5+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Tendinopathy product details are provided in the report. Download the Tendinopathy pipeline report to learn more about the emerging Tendinopathy therapies at:
https://www.delveinsight.com/sample-request/tendinopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key companies in the Tendinopathy Therapeutics Market include:
Key companies developing therapies for Tendinopathy are - Zimmer Biomet, 3M, AKSIGEN, Smith+Nephew, Stryker, OssurTynor India, Colfax Corporation (DJO Global Inc.), Teikoku Pharma USA Inc., Merck and Co., Inc., Almatica Pharma, Inc., Teva Pharmaceuticals, and others.

Tendinopathy Pipeline Analysis:
The Tendinopathy pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Tendinopathy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Tendinopathy Treatment.
• Tendinopathy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Tendinopathy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Tendinopathy market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Tendinopathy drugs and therapies-
https://www.delveinsight.com/sample-request/tendinopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Tendinopathy Pipeline Market Drivers
• Increasing Incidence of Tendinopathy, Advances in Regenerative Medicine, Growing Focus on Non-surgical Treatment Options, R&D Investment in Musculoskeletal Conditions, are some of the important factors that are fueling the Tendinopathy Market.

Tendinopathy Pipeline Market Barriers
• However, Limited Efficacy of Current Treatments, Regulatory Challenges, High Treatment Costs, Complexity of Tendon Healing Mechanisms , and other factors are creating obstacles in the Tendinopathy Market growth.

Scope of Tendinopathy Pipeline Drug Insight
• Coverage: Global
• Key Tendinopathy Companies: Causeway Therapeutics, Novartis, ZARS Pharma Inc., Merck Sharp, Erasmus Medical Center, CTM Biomedical, Zimmer Biomet, 3M, Teikoku Pharma USA Inc., DJO Global Inc., AKSIGEn, and others
• Key Tendinopathy Therapies: CWT-001, secukinumab, NGI226, Heated Lidocaine and Tetracaine Patch, etoricoxib, PRP Injection with eccentric exercises, Celestone, and others
• Tendinopathy Therapeutic Assessment: Tendinopathy current marketed and Tendinopathy emerging therapies
• Tendinopathy Market Dynamics: Tendinopathy market drivers and Tendinopathy market barriers

Request for Sample PDF Report for Tendinopathy Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/tendinopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Tendinopathy Report Introduction
2. Tendinopathy Executive Summary
3. Tendinopathy Overview
4. Tendinopathy- Analytical Perspective In-depth Commercial Assessment
5. Tendinopathy Pipeline Therapeutics
6. Tendinopathy Late Stage Products (Phase II/III)
7. Tendinopathy Mid Stage Products (Phase II)
8. Tendinopathy Early Stage Products (Phase I)
9. Tendinopathy Preclinical Stage Products
10. Tendinopathy Therapeutics Assessment
11. Tendinopathy Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Tendinopathy Key Companies
14. Tendinopathy Key Products
15. Tendinopathy Unmet Needs
16 . Tendinopathy Market Drivers and Barriers
17. Tendinopathy Future Perspectives and Conclusion
18. Tendinopathy Analyst Views
19. Appendix
20. About DelveInsight

Trending Reports:
• Wet-age Related Macular Degeneration Market: https://www.delveinsight.com/report-store/wet-age-related-macular-degeneration-wet-amd-market
• Acne Vulgaris Market: https://www.delveinsight.com/report-store/acne-vulgaris-av-market
• Acoustic Neuroma Market: https://www.delveinsight.com/report-store/vestibular-schwannoma-market
• Acquired Hemophilia A Pipeline: https://www.delveinsight.com/report-store/acquired-hemophilia-a-pipeline-insight
• Acute Coronary Syndrome Market: https://www.delveinsight.com/report-store/acute-coronary-syndrome-market
• Acute Heart Failure Ahf Market: https://www.delveinsight.com/report-store/acute-heart-failure-ahf-market
• Acute Ocular Pain And Inflammation Market: https://www.delveinsight.com/report-store/acute-ocular-pain-market-insights
• Advanced Recurrent Ovarian Cancer Market: https://www.delveinsight.com/report-store/advanced-recurrent-ovarian-cancer-market
• Aesthetic Implants Market: https://www.delveinsight.com/report-store/aesthetic-implants-market
• Aids Related Kaposi's Sarcoma Market: https://www.delveinsight.com/report-store/aids-related-kaposis-sarcoma-market
• Airway Stent Market Market: https://www.delveinsight.com/report-store/airway-stent-market
• Allergic Asthma Due To Dermatophagoides Farinae Market: https://www.delveinsight.com/report-store/allergic-asthma-due-to-dermatophagoides-farinae-market
• Allergic Rhinoconjunctivitis Market: https://www.delveinsight.com/report-store/allergic-rhinitis-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Tendinopathy Pipeline Analysis 2025: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Therapies, Mechanism of Action, Route of Administration, and Companies by DelveInsight here

News-ID: 4112790 • Views:

More Releases from DelveInsight Business Research

Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibrillation Space by DelveInsight
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals. Objective of the Case Study The
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestones, Therapies in Development, Mechanisms of Action, and Routes of Administration - By DelveInsight
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics. According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Rising Cancer Burden and Technological Advancements, states DelveInsight
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies. Biopsy devices play a crucial role in disease diagnosis by
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven by Rising Surgical Procedures, Technological Advancements, and Growing Adoption of Minimally Invasive Techniques, States DelveInsight
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide. DelveInsight's General Surgery Devices Market Report 2032 provides

All 5 Releases


More Releases for Tendinopathy

Tendinopathy Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Tendinopathy pipeline constitutes 5+ key companies continuously working towards developing 5+ Tendinopathy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Tendinopathy Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Tendinopathy Market. The Tendinopathy Pipeline report embraces in-depth
Tendinopathy Market Outlook: Growth Driven by Sports Injuries, Biologics & Advan …
The Global Tendinopathy Market reached US$ 215.26 billion in 2023 and is expected to reach US$ 299.16 billion by 2031 growing with a CAGR of 4.2% during the forecast period 2024-2031. The tendinopathy market focuses on the diagnosis, treatment, and management of tendinopathy, a condition characterized by pain, swelling, and impaired tendon function caused by overuse, injury, or degeneration. Common types include Achilles, rotator cuff, patellar, and lateral epicondylitis
Tendinopathy Market Size, Share and Competitive Landscape
Tendinopathy refers to the condition where the tendons, which are the thick fibrous tissues that connect muscles to bones, become damaged or inflamed, leading to pain, swelling, and restricted movement. It is a common issue for athletes, manual laborers, and aging populations. The tendinopathy market is growing rapidly, driven by the rising incidence of sports injuries, increasing healthcare access, and advancements in treatments, including biologics, physical therapy, and surgical interventions.
Tendinopathy Market is expected to reach US$ 299.16 billion by 2031- Zimmer Biom …
The Tendinopathy Market study by DataM Intelligence offer an in-depth analysis of the market, presenting insightful observations, statistics, historical data, and industry-validated market insights. The report delves into the competitive positioning of key companies, examining factors such as product offerings, pricing strategies, financial health, product portfolios, growth initiatives, and geographical reach. Download a Free sample PDF (Use Corporate email ID to Get Higher Priority) at: - https://datamintelligence.com/download-sample/tendinopathy-market What is the projected growth
Tendinopathy Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, E …
(Albany, USA) The Tendinopathy market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as MiMedx Group, Novartis Pharmaceuticals, Ipsen, Orthocell Limited, ZARS Pharma Inc., Zimmer Biomet, Causeway Therapeutics, Travanti Pharma Inc., Abbisko Therapeutics Co, Ltd, Deciphera Pharmaceuticals, LLC, Daiichi Sankyo, AmMax Bio, Inc., AmMax Bio, Inc., DelveInsight's "Tendinopathy Market Insights, Epidemiology, and Market Forecast 2034."
Tendinopathy Market Forecasted for Substantial Growth (2024-2031) | Zimmer Biome …
The Tendinopathy Market study by DataM Intelligence offer an in-depth analysis of the market, presenting insightful observations, statistics, historical data, and industry-validated market insights. The report delves into the competitive positioning of key companies, examining factors such as product offerings, pricing strategies, financial health, product portfolios, growth initiatives, and geographical reach. Get a Free Sample PDF - https://datamintelligence.com/download-sample/tendinopathy-market What is the projected growth rate (CAGR) of the Global Tendinopathy market from 2024